Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia

作者：Zhen Gao, Hong Pan, Lele Zhang, Weiwang Li, Ruonan Li, Jingyu Zhao, Yuechen Luo, Yu Lian, Xiao Yu, Zhexiang Kuang, Neng Nie, Jianping Li, Jinbo Huang, Xin Zhao, Yuan Li, Liwei Fang, Meili Ge, Yizhou Zheng, Jun Shi · 发表于：Blood · 年份：2025 · DOI：10.1182/blood.2025029006 · 被引用次数：3 · 研究领域：Calcium signaling and nucleotide metabolism、Blood groups and transfusion、Chronic Lymphocytic Leukemia Research

ABSTRACT: We found that 8 of 10 patients with aplastic anemia experienced resolution of platelet transfusion refractoriness following daratumumab administration. Notably, 4 responders achieved hematopoietic recovery, including 3 participants who showed improvements in multilineage blood cell counts, even with daratumumab monotherapy. This trial was registered at www.clinicaltrials.gov as #NCT05832216.